â– LECTURE OVERVIEW: Phosphofructokinase-1 (PFK-1) is the primary rate-limiting and committed enzyme of the glycolytic pathway, catalyzing the transfer of a phosphate group from ATP to Fructose-6-Phosphate (F-6-P) to yield Fructose-1,6-Bisphosphate (F-1,6-BP).
â– MOLECULAR DYNAMICS & ALLOCATIONS:
1. High Energy Charge Inhibitors: ATP and Citrate bind to allosteric inhibitory sites, shifting the enzyme's conformational state from high-affinity 'R' (relaxed) to low-affinity 'T' (tense) state. High ATP signals abundant cellular energy, rendering glycolysis redundant.
2. Low Energy Charge Activators: AMP and ADP act as allosteric activators, reversing the inhibitory effect of ATP.
3. Master Regulator (F-2,6-BP): Fructose-2,6-bisphosphate (F-2,6-BP) is the most potent allosteric activator of PFK-1. It is synthesized and degraded by the bifunctional enzyme Phosphofructokinase-2 / Fructose-2,6-Bisphosphatase (PFK-2 / FBPase-2).
4. Hormonal Super-coordination: Insulin dephosphorylates the PFK-2/FBPase-2 complex, activating the kinase (PFK-2) and raising F-2,6-BP levels to drive glycolysis. Glucagon phosphorylates the complex via Protein Kinase A, activating the phosphatase (FBPase-2) to deplete F-2,6-BP, shifting hepatocytes to gluconeogenesis.
â– SURGICAL LANDMARKS & ANATOMICAL BOUNDARIES:
Intraoperative access requires meticulous dissection along defined tissue planes. Avoid excessive traction near neurovascular bundles and look for key bony landmarks or fascial reflections to secure margins.
â– MOLECULAR PATHWAY DYNAMICS:
Intracellular cascades undergo profound modifications, altering secondary transcription levels and receptor presentation on cellular membranes.
[HY-BOARD-1073]
🌟 Dynamic Clinical Key:
In diabetic ketoacidosis (DKA), a profound lack of insulin elevates glucagon, driving PFK-2 phosphorylation and F-2,6-BP depletion. This completely inhibits PFK-1, halting glycolysis and switching the hepatic metabolic machinery to uninhibited gluconeogenesis, which worsens hyperglycemia. Never divide or ligate any vessel before clearly isolating and confirming its origin and termination. Therapeutic molecules targeting upstream signaling components demonstrate superior efficacy profiles.